



Ringly Inc.  
39 W 14<sup>th</sup> St Suite  
New York, NY 10011

Re: Confidentiality Request regarding application for certification of FCC ID: 2AB9V-0014  
Date: October 12, 2016

Federal Communications Commission  
Authorization and Evaluation Division

Pursuant to Sections 0.457 and 0.459 of the Commission's Rules, we hereby request confidential treatment of information accompanying this application as outlined below:

<b>Exhibit Type</b>	<b>File Name</b>
Block Diagram	2AB9V-0014 BlkDia.pdf
Schematics	2AB9V-0014 Schem.pdf
Operational Description	2AB9V-0014 OpDes.pdf

The above materials contain trade secrets and proprietary information not customarily released to the public. The public disclosure of these materials may be harmful to the applicant and provide unjustified benefits to its competitors.

The applicant understands that pursuant to Section 0.457 of the Rules, disclosure of this application and all accompanying documentation will not be made before the date of the Grant for this application.

Pursuant to DA04-1705 June 15, 2004 of the Commission's public notice, we also require temporary confidential treatment of information accompanying this application as outlined below: for 180 days.

<b>Exhibit Type</b>	<b>File Name</b>
Internal Photos	2AB9V-0014 IntPho.pdf

Temporary confidentiality from public disclosure is important for Ringly from a commercial perspective. It enables the company to complete its development and regulatory efforts prior to introducing the product to the marketplace. Releasing information on the product via the FCC website prior to formal market introduction can be confusing to our customers and the medical community, and places the company at a competitive disadvantage.

Sincerely,

Logan Munro